Activation of peptide prodrugs by hK2
US7053042B1 · kind B1 · utility
16Cited by
8References
40Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 28, 2000 |
| Grant date | May 30, 2006 |
| Priority date | — |
| Expiry date | Jan 4, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/47
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.